CR20210394A - Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo - Google Patents

Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo

Info

Publication number
CR20210394A
CR20210394A CR20210394A CR20210394A CR20210394A CR 20210394 A CR20210394 A CR 20210394A CR 20210394 A CR20210394 A CR 20210394A CR 20210394 A CR20210394 A CR 20210394A CR 20210394 A CR20210394 A CR 20210394A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical compositions
crystalline
organic compound
salts
salt forms
Prior art date
Application number
CR20210394A
Other languages
English (en)
Inventor
Syed Altaf
Jacob Sizemore
Shijie Zhang
Abira Ramakrishnan
Original Assignee
Les Laboratoires Servier Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier Sas filed Critical Les Laboratoires Servier Sas
Publication of CR20210394A publication Critical patent/CR20210394A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proporcionan diversas sales, que incluyen sales de tris(hidroximetil)aminometano y sales de sodio, así como diversas formas cristalinas del compuesto representado por la fórmula estructural: También se proporcionan composiciones farmacéuticas que comprenden estas sales y formas cristalinas, métodos para su fabricación, y usos de las mismas para tratar condiciones, incluyendo, pero no limitado a, condiciones que se beneficiarían de la inhibición de dihidroorotato deshidrogenasa (DHODH).
CR20210394A 2018-12-21 2019-12-20 Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo CR20210394A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862784083P 2018-12-21 2018-12-21
US201962791571P 2019-01-11 2019-01-11
US201962882712P 2019-08-05 2019-08-05
PCT/US2019/067897 WO2020132471A1 (en) 2018-12-21 2019-12-20 Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
CR20210394A true CR20210394A (es) 2021-12-13

Family

ID=69185721

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210394A CR20210394A (es) 2018-12-21 2019-12-20 Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo

Country Status (20)

Country Link
US (1) US20220055995A1 (es)
EP (1) EP3898597A1 (es)
JP (1) JP2022515239A (es)
KR (1) KR20220035022A (es)
CN (1) CN113508108A (es)
AU (1) AU2019403396A1 (es)
BR (1) BR112021012305A2 (es)
CA (1) CA3124401A1 (es)
CL (1) CL2021001640A1 (es)
CO (1) CO2021009309A2 (es)
CR (1) CR20210394A (es)
IL (1) IL284218A (es)
JO (1) JOP20210147A1 (es)
MA (1) MA54541A (es)
MX (1) MX2021007536A (es)
NI (1) NI202100055A (es)
PE (1) PE20212197A1 (es)
SG (1) SG11202106526UA (es)
TW (1) TW202039448A (es)
WO (1) WO2020132471A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019164794A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
CN116847874A (zh) 2020-08-27 2023-10-03 瑟维尔实验室 Dhodh抑制剂化合物在组合癌症疗法中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024785A2 (en) * 1999-10-01 2001-04-12 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
JP2007015952A (ja) * 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
EP2228367A1 (en) * 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2230232A1 (en) * 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
US9360932B1 (en) 2012-08-29 2016-06-07 Intellect Motion Llc. Systems and methods for virtually displaying real movements of objects in a 3D-space by means of 2D-video capture
CN103965133B (zh) * 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
PT3019482T (pt) * 2013-02-25 2018-11-28 Aurigene Discovery Tech Ltd Derivados de benzotriazole trissubstituídos enquanto inibidores de di-hidro-orotato-oxigenase
US20180369206A1 (en) * 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
WO2019164794A1 (en) * 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
EP4171552A1 (en) * 2020-06-24 2023-05-03 Les Laboratoires Servier Use of a dhodh inhibitor compound in combination cancer therapy
CN116847874A (zh) * 2020-08-27 2023-10-03 瑟维尔实验室 Dhodh抑制剂化合物在组合癌症疗法中的用途

Also Published As

Publication number Publication date
CA3124401A1 (en) 2020-06-25
JP2022515239A (ja) 2022-02-17
WO2020132471A8 (en) 2020-08-06
NI202100055A (es) 2021-12-01
MX2021007536A (es) 2021-09-23
IL284218A (en) 2021-08-31
AU2019403396A1 (en) 2021-07-08
CL2021001640A1 (es) 2022-06-03
PE20212197A1 (es) 2021-11-16
EP3898597A1 (en) 2021-10-27
CN113508108A (zh) 2021-10-15
BR112021012305A2 (pt) 2021-10-05
CO2021009309A2 (es) 2021-10-29
MA54541A (fr) 2022-03-09
US20220055995A1 (en) 2022-02-24
TW202039448A (zh) 2020-11-01
WO2020132471A1 (en) 2020-06-25
JOP20210147A1 (ar) 2023-01-30
KR20220035022A (ko) 2022-03-21
SG11202106526UA (en) 2021-07-29

Similar Documents

Publication Publication Date Title
MX2024008497A (es) Fabricacion de compuestos y composiciones para inhibir la actividad de shp2.
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201690094A1 (ru) Ингибиторы syk
EA201890752A1 (ru) Способ получения противогрибковых соединений
MX2020007265A (es) Derivados de rapamicina.
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
EA201891553A1 (ru) Ингибиторы syk
EA201990833A1 (ru) Соединение пиридина
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
MX2018006390A (es) Composiciones y metodos para tratar accidente cerebrovascular isquemico.
EA201891770A1 (ru) Малеатная соль агониста tlr7, ее кристаллические формы c, d и e, способы получения и применение малеатной соли и кристаллических форм
MX2018001991A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
EA201690755A1 (ru) Солевые и кристаллические формы ингибитора plk-4
MX2018008671A (es) Composicion para incrementar la expresion de pgc-1alfa.
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
JOP20210147A1 (ar) صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه
EA201892020A1 (ru) Индольные производные и их применение в качестве ингибиторов протеинкиназы
WO2018125983A8 (en) Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
EA201690818A1 (ru) Замещенные пиримидиновые соединения и их применение в качестве syk ингибиторов